Phenylmethylsulfonyl fluoride protects rats from Mipafox-induced delayed neuropathy.
Initiation of organophosphorus-induced delayed neuropathy (OPIDN) is thought to consist of two molecular events involving the phosphorylation of the target enzyme, neurotoxic esterase, or neuropathy target enzyme (NTE), and a subsequent "aging" reaction which transforms the inhibited NTE into a charged moiety critical to the neuropathic process. Compounds that inhibit NTE but cannot age because of their chemical structure abort this two-stage initiation process, and when administered before a neurotoxic organophosphorus compound (OP), protect against the neuropathy by blocking NTE's active site (Johnson, 1970). In support of this, we report that prior exposure to a nonaging NTE inhibitor, phenylmethylsulfonyl fluoride (PMSF), protects rats from neurological damage after subsequent exposure to a neurotoxic OP, Mipafox. Adult, male, Long Evans rats were exposed to either PMSF (250 mg/kg, sc) or to Mipafox (15 mg/kg, ip) and a time course of brain NTE inhibition and recovery was defined. A separate group of PMSF-treated rats was exposed to Mipafox when brain NTE inhibition was 87.7 +/- 2.3%. Conversely, another group of rats, pretreated with Mipafox, was dosed with PMSF when NTE inhibition was 90.2 +/- 0.8%. A third group of animals, treated with PMSF, was exposed to Mipafox 14 days later, when NTE activity had recovered to within 10 +/- 4.2% of control amounts. Histopathological survey (14 to 21 days post-exposure) indicated severe cervical cord damage (damage score greater than or equal to 3) in the following frequencies: PMSF, 0%; Mipafox, 85%; PMSF-4 hr-Mipafox, 0%; Mipafox-4 hr-PMSF, 100%; PMSF-14 days-Mipafox, 75%; controls, 0%. These data indicate that PMSF pretreatment protects rats against Mipafox-induced neurological damage and that the timing of administration and order of presentation are critical to this protection. These results support the hypothesis that the initiation of OPIDN is a multistage event involving inhibition and aging, and these stages are experimentally separable.
D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000201:enzymology; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007531:Isoflurophate / Q000031:analogs & derivatives* / Q000633:toxicity; D008297:Male; D009422:Nervous System Diseases / Q000139:chemically induced; D010664:Phenylmethylsulfonyl Fluoride / Q000494:pharmacology*; D051381:Rats; D013116:Spinal Cord / Q000473:pathology; D013450:Sulfones / Q000494:pharmacology*
D013450:Sulfones; D007531:Isoflurophate; C005238:mipafox; D010664:Phenylmethylsulfonyl Fluoride